Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, Brazilian Phase II trial in 146 evaluable patients, moxifloxacin plus isoniazid, rifampin and pyrazinamide
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury